Filing Flows › Comparisons › TECH vs RGEN
Bio-Techne vs Repligen: TECH and RGEN compared
Bio-Techne is the larger company: $300M of revenue in its latest quarter (Q1 FY27) against $209M for Repligen (Q3 2026). Repligen is growing faster (+11% against +5% a year earlier). Bio-Techne is more profitable, with an operating margin of 12.2% against -14.1%.
Where the money goes: TECH and RGEN
Bio-Techne (TECH) · Q1 FY27
Bio-Techne, Q1 FY27: revenue $300M (+5% year over year), operating margin 12.2%, net earnings $28.3M, operating cash flow $73.1M. The chart follows the revenue to costs, profit and cash.
Repligen (RGEN) · Q3 2026
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart follows the revenue to costs, profit and cash.
| Bio-Techne (TECH) | Repligen (RGEN) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q3 2026 |
| Revenue | $300M | $209M |
| Revenue growth, Y/Y | +5% | +11% |
| Gross margin | 65.6% | — |
| Operating margin | 12.2% | -14.1% |
| Net earnings | $28.3M | −$38.4M |
| Net margin | 9.4% | -18.4% |
| Operating cash flow | $73.1M | $43.1M |
| Free cash flow | $67.2M | $38.2M |
| Market value | $11.4B | $9.9B |
| P/E | 62.9× | — |
| Analysts’ mean target | $70.50 | $203.45 |
Where the revenue comes from
Bio-Techne
- Product and Services: $285M (95%)
- Royalty: $14.5M (5%)
Repligen
- Product: $209M (100%)
- Royalty and other revenue: $44K (0%)
Questions
Which is bigger, Bio-Techne or Repligen?
Bio-Techne is the larger company: $300M of revenue in its latest quarter (Q1 FY27) against $209M for Repligen (Q3 2026).
Is Bio-Techne or Repligen growing faster?
Repligen is growing faster (+11% against +5% a year earlier).
Which is more profitable, Bio-Techne or Repligen?
Bio-Techne is more profitable, with an operating margin of 12.2% against -14.1%.
More: Bio-Techne earnings · how Bio-Techne makes money · Repligen earnings · how Repligen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.